Communiqués Spyre Therapeutics, Inc.

Actions

SYRE

US00773J2024

Recherche biotechnologique et médicale

Marché Fermé - 22:00:00 04/09/2026 Varia. 5j. Varia. 1 janv.
88,98 USD +1,98% Graphique intraday de Spyre Therapeutics, Inc. -4,95% +171,61%

Communiqués

04/09 Spyre Therapeutics Announces Grants of Inducement Awards AQ
03/09 Spyre Therapeutics to Participate in Upcoming September Investor Conferences GL
25/08 Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 GL
10/08 Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa GL
07/08 Spyre Therapeutics Announces Grants of Inducement Awards AQ
04/08 Spyre Therapeutics: Q2 Earnings Snapshot AQ
04/08 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update GL
02/07 Spyre Therapeutics Announces Grants of Inducement Awards AQ
15/06 Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients GL
15/06 Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients AQ
05/06 Spyre Therapeutics Announces Grants of Inducement Awards AQ
03/06 Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA GL
26/05 Spyre Therapeutics to Participate in Upcoming June Investor Conferences GL
05/05 Spyre Therapeutics: Q1 Earnings Snapshot AQ
05/05 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GL
01/05 Spyre Therapeutics Announces Grants of Inducement Awards AQ
16/04 Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million GL
15/04 Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock GL
13/04 Spyre Therapeutics Announces Proposed Public Offering of its Common Stock GL
13/04 Spyre Therapeutics : SKYLINE A SPY001 vFINAL PU
13/04 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients GL
10/04 Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 GL
03/04 Spyre Therapeutics Announces Grants of Inducement Awards AQ
16/03 Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 GL
06/03 Spyre Therapeutics Announces Grants of Inducement Awards AQ
Aucun résultat pour cette recherche